Ac225Actinium 225

Actinium-225 is a radioisotope used for treatment in targeted alpha therapy. It has a half-life of 10 days. Clinical trials have demonstrated the applicability of radiopharmaceuticals containing 225Ac to treat various types of cancer including leukaemia, prostate cancer and primary tumours.

To produce Actinium 225,
we recommend this production route:

  • Recommended

    Accelerator:

    Rhodotron® TT300 HE

    Target:

    Custom target

    Chemistry:

    Hardware ready

    Process under development